Overview

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This pilot study is crucial to determining whether treating individuals who are at high risk for transmission or re-infection will impact HCV reinfection rates. It will establish the feasibility of DAA treatment in corrections facilities, as well as delineate the underlying immune basis of HCV cure and reinfection.
Phase:
Phase 4
Details
Lead Sponsor:
Lisa Barrett
Collaborator:
PEI Provincial Correction Centre
Treatments:
Interferons
Ribavirin
Ritonavir